DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tesofensine
Tesofensine
Experimental Dopamine Reuptake Inhibitors in Parkinson’S Disease: a Review of the Evidence
Study Protocol
(19) United States (12) Patent Application Publication (10) Pub
Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
Monoamine Reuptake Inhibitors in Parkinson's Disease
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Anti-Obesity Drugs: a Review About Their Effects and Their Safety
Pharmacotherapy of Obesity: Limits and Perspectives
Redalyc.Update on Pharmacology of Obesity: Benefts and Risks
Anti-Obesity Drugs: a Review About Their Effects and Safety
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
List of SSRI Effects Spirits for MD Widespread Use of Antidepressants
Triple Reuptake Inhibitors: the Next Generation of Antidepressants
Discovery of Novel-Scaffold Monoamine Transporter Ligands Via in Silico Screening with the S1 Pocket Of
Tesofensine, a Novel Triple Monoamine Reuptake
Synthesis and Evaluation of Novel Tropane Compounds As Potential Therapeutics for Drug Abuse
Continuing Education
Top View
Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
Rana Dadashova
MCLELLAND Angela Estelle
Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor
The Effect of the Triple Monoamine Reuptake Inhibitor Tesofensine on Energy Metabolism and Appetite in Overweight and Moderately Obese Men
Pharmaabkommen A1 E
Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients with Advanced Parkinson Disease and Motor Fluctuations the ADVANS Study
New and Emerging Drug Molecules Against Obesity
Customs Tariff - Schedule Xxi - 1
(12) Patent Application Publication (10) Pub. No.: US 2016/0000815 A1 BIRD (43) Pub
Obesity/Lipids
New Anti-Obesity Drugs on the Horizon
Tesofensine-A Novel Potent Weight Loss Medicine
Module 1. Signalering – Concept Voor Commentaarronde
Table [1]: Definition of Reported Outcomes Study Outcome
Clinical Study Protocol
Customs Tariff - Schedule
(12) United States Patent (10) Patent No.: US 8,957,099 B2 Bird (45) Date of Patent: Feb
Anti-Obesity Drugs: a Review About Their Effects and Safety
UWA-121, a Mixed Dopamine and Serotonin Re-Uptake Inhibitor, Enhances L-DOPA Anti-Parkinsonian Action Without Worsening Dyskines
Monoamines and Anhedonia